Novo Nordisk A/S (NVO): A Bull Case Theory

We came across a bullish thesis on Novo Nordisk A/S on Summit Stocks’s Substack by Summit Stocks. In this article, we will summarize the bulls’ thesis on NVO. Novo Nordisk A/S 's share was trading at $56.74 as of September 3^rd. NVO’s trailing and forward P/E were 14.49 and 13.48 respectively according to Yahoo Finance.

During a double press release, Novo Nordisk delivered a double shock with a sales warning and the appointment of a new CEO, sending shares down 20% on the day and another 6% the following session, erasing over $60 billion in market value. The reaction stands in stark...